XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Balance at Dec. 31, 2022   $ 1 $ 422,981 $ (1,316) $ (405,727) $ 15,939
Balance (in shares) at Dec. 31, 2022 573,282 628,139        
Stock-based compensation     401     401
Preferred stock dividends     (50)     (50)
Unrealized foreign exchange on intercompany loans       5,263   5,263
Translation adjustment       (5,171)   (5,171)
Loss for the period         (5,804) (5,804)
Balance at Mar. 31, 2023   $ 1 423,332 (1,224) (411,531) 10,578
Balance (in shares) at Mar. 31, 2023 573,282 628,139        
Balance at Dec. 31, 2022   $ 1 422,981 (1,316) (405,727) 15,939
Balance (in shares) at Dec. 31, 2022 573,282 628,139        
Unrealized foreign exchange on intercompany loans           10,840
Translation adjustment           (10,621)
Loss for the period           (11,252)
Balance at Jun. 30, 2023   $ 1 424,746 (1,097) (416,979) 6,671
Balance (in shares) at Jun. 30, 2023 573,282 681,352        
Balance at Mar. 31, 2023   $ 1 423,332 (1,224) (411,531) 10,578
Balance (in shares) at Mar. 31, 2023 573,282 628,139        
Issue of common stock in At Market Issuance sales agreement, net of expenses     1,105     1,105
Issue of common stock in At Market Issuance sales agreement, net of expenses (in shares)   53,213        
Stock-based compensation     359     359
Preferred stock dividends     (50)     (50)
Unrealized foreign exchange on intercompany loans       5,577   5,577
Translation adjustment       (5,450)   (5,450)
Loss for the period         (5,448) (5,448)
Balance at Jun. 30, 2023   $ 1 424,746 (1,097) (416,979) 6,671
Balance (in shares) at Jun. 30, 2023 573,282 681,352        
Balance at Dec. 31, 2023   $ 1 429,796 (908) (428,282) 607
Balance (in shares) at Dec. 31, 2023 454,537 1,058,892        
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering     (80)     (80)
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering (in shares)   219,700        
Series B Preferred stock conversions (in shares) (119,000) 39,667        
Stock-based compensation     203     203
Unrealized foreign exchange on intercompany loans       (2,130)   (2,130)
Translation adjustment       2,140   2,140
Loss for the period         (2,946) (2,946)
Balance at Mar. 31, 2024   $ 1 429,919 (898) (431,228) (2,206)
Balance (in shares) at Mar. 31, 2024 335,537 1,318,259        
Balance at Dec. 31, 2023   $ 1 429,796 (908) (428,282) 607
Balance (in shares) at Dec. 31, 2023 454,537 1,058,892        
Unrealized foreign exchange on intercompany loans           (1,626)
Translation adjustment           1,619
Loss for the period           (6,203)
Balance at Jun. 30, 2024   $ 2 436,397 (915) (434,485) 999
Balance (in shares) at Jun. 30, 2024 335,537 1,805,204        
Balance at Mar. 31, 2024   $ 1 429,919 (898) (431,228) (2,206)
Balance (in shares) at Mar. 31, 2024 335,537 1,318,259        
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses   $ 1 6,289     6,290
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses (in shares)   486,945        
Stock-based compensation     189     189
Unrealized foreign exchange on intercompany loans       504   504
Translation adjustment       (521)   (521)
Loss for the period         (3,257) (3,257)
Balance at Jun. 30, 2024   $ 2 $ 436,397 $ (915) $ (434,485) $ 999
Balance (in shares) at Jun. 30, 2024 335,537 1,805,204